Artivion (AORT) Stock Price, News & Analysis

Company Overview

Artivion, Inc. (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation. Headquartered in Kennesaw, Georgia, Artivion operates manufacturing and processing facilities in the United States and Europe, with commercial teams serving hospitals and surgical centers across North America, Latin America, Europe, the Middle East and Asia-Pacific. Its global footprint is supported by direct sales operations and distribution partnerships that deliver both off-the-shelf and custom tissue solutions to clinicians worldwide.

Leadership at Artivion is focused on expanding the company’s product pipeline through research and development initiatives and strategic acquisitions. Under the direction of CEO Paul F. Le Gars, the company has pursued regulatory approvals across multiple markets and invested in next-generation tissue processing technologies. Through this combination of biologic innovation and device engineering, Artivion aims to address unmet clinical needs in cardiovascular surgery and improve patient outcomes over the long term.

Key Stats

• Today's Range: $25.79 to $27.32
• 50-Day Range: $20.04 to $27.67
• 52-Week Range: $19.16 to $48.25
• Volume: 964,006 shs
• Average Volume: 545,356 shs
• Market Capitalization: $1.27 billion
• P/E Ratio: 109.43
• Dividend Yield: N/A
• Price Target: $44.17
• Consensus Rating: Moderate Buy

Artivion Stock Analysis - MarketRank™

Artivion scored higher than 87% of companies evaluated by MarketBeat, and ranked 71st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Artivion has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Artivion has a consensus price target of $44.17, representing about 68.2% upside from its current price of $26.26.

Amount of Analyst Coverage

Artivion has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 50.00%

Earnings Growth

Earnings for Artivion are expected to grow by 50.00% in the coming year, from $0.50 to $0.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artivion is 109.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artivion is 109.43, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 280.40.

Price to Book Value per Share Ratio

Artivion has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.49% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 4.54.

Change versus previous month

Short interest in Artivion has recently increased by 14.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artivion does not currently pay a dividend.

Dividend Growth

Artivion does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.03

News Sentiment

Artivion has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Artivion this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for AORT on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,821.00 in company stock.

Percentage Held by Insiders

6.30% of the stock of Artivion is held by insiders.

Percentage Held by Institutions

86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/12/2026
• Today: 8/05/2026
• Next Earnings (Estimated): 8/06/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:AORT
• CIK: 784199
• Web: www.cryolife.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,800
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Artivion: $44.17
• High Price Target: $50.00
• Low Price Target: $36.00
• Potential Upside/Downside: +68.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.24
• Trailing P/E Ratio: 109.43
• Forward P/E Ratio: 52.52
• P/E Growth: N/A
• Net Income: $9.77 million
• Net Margins: 2.55%
• Pretax Margin: 3.80%
• Return on Equity: 7.15%
• Return on Assets: 3.63%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 3.86
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $441.33 million
• Price / Sales: 2.89
• Cash Flow: $1.08 per share
• Price / Cash Flow: 24.41
• Book Value: $9.46 per share
• Price / Book: 2.78

Miscellaneous

• Outstanding Shares: 48,540,000
• Free Float: 45,485,000
• Market Cap: $1.27 billion
• Optionable: Optionable
• Beta: 1.25